Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Outlook Therapeutics, Inc. (OTLK) is a Biotechnology company based in US with a market capitalization of $30M. Free cash flow was negative at -$51.8T. This page tracks OTLK's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 23 employees · IPO Jun 14, 2016
Valuation
Valuation & price
$0.23as of May 17, 2026· -92.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$30M
Market cap
—
Revenue growth (YoY)
46.5%
Gross margin
-$51.8T
Free cash flow (USD)
$22.1M
Net debt
87.6%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Value screen
Graham defensive-investor tests
6
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 15, 2026 (EPS $-0.16)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 26, 2026Filing
Regained Compliance
- 8-K eventJun 16, 2026Filing
FDA BLA Resubmission Acknowledged
- Insider buyJun 3, 2026Filing
Insider Buy $24KHaddadin Yezan Munther · Director · $24.1K
- Insider buyJun 1, 2026Filing
Insider Buy $5.0MSukhtian Ghiath M. · Director, 10% Owner · $5M
- 8-K eventJun 1, 2026Filing
Biologics License Application Resubmission
- 8-K eventMay 29, 2026Filing
Registered Direct Offering
- 8-K eventMay 28, 2026Filing
Securities Purchase Agreement
- Insider buyMay 27, 2026Filing
Insider Buy $177KHILZINGER KURT J · Director · $176.5K
- Insider buyMay 27, 2026Filing
Insider Buy $2KTHURMAN RANDY H · Director · $2.1K
- Insider buyMay 27, 2026Filing
Insider Buy $15KHaddadin Yezan Munther · Director · $15K
Questions
Frequently asked questions
What is Outlook Therapeutics, Inc.'s market cap?
Outlook Therapeutics, Inc. (OTLK) has a market capitalization of $30M.
What is OTLK's P/E ratio?
A meaningful P/E ratio is not available for OTLK — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
When did Outlook Therapeutics, Inc. last report earnings?
OTLK last reported earnings on May 15, 2026; the next date is not yet scheduled.
Are insiders buying OTLK stock?
Yes — SEC Form 4 filings show 6 open-market insider buys and 0 sells at Outlook Therapeutics, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.